Health Trials

Hormonal, Metabolic, and Signaling Interactions in PAH

ConditionsIdiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionScleroderma Associated Pulmonary Arterial HypertensionAppetite Suppressant Associate PAH
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 90
SponsorVanderbilt University Medical Center

About this trial

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

Eligibility criteria

Qualifiers

Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons

Age 0-90, age 12-90 for skin biopsy

Other diagnosis

Age greater than 90, age less than 12 or greater than 90 for skin biopsy

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,899 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Vanderbilt University Medical Center

Lead sponsor

Source ClinicalTrials.gov